{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:00:14Z","timestamp":1780588814407,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"DOI":"10.7759\/cureus.83283","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:17:18Z","timestamp":1746083838000},"source":"Crossref","is-referenced-by-count":1,"title":["An Unusual Case of Transthyretin Cardiac Amyloidosis Presenting as Heart Failure With Improved Ejection Fraction Without Left Ventricular Hypertrophy"],"prefix":"10.7759","author":[{"given":"Satoshi","family":"Kurisu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka H","year":"2020","unstructured":"Kitaoka H, Izumi C, Izumiya Y, et al.. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J. 2020, 84:1610-71. 10.1253\/circj.CJ-20-0110","journal-title":"Circ J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson MM","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, et al.. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020, 142:e7-22. 10.1161\/CIR.0000000000000792","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13473","article-title":"Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm","volume":"8","author":"Inomata T","year":"2021","unstructured":"Inomata T, Tahara N, Nakamura K, et al.. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm. ESC Heart Fail. 2021, 8:2647-59. 10.1002\/ehf2.13473","journal-title":"ESC Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123226","article-title":"Transthyretin cardiac amyloidosis: a cardio-orthopedic disease","volume":"10","author":"Perfetto F","year":"2022","unstructured":"Perfetto F, Zampieri M, Bandini G, et al.. Transthyretin cardiac amyloidosis: a cardio-orthopedic disease. Biomedicines. 2022, 10:3226. 10.3390\/biomedicines10123226","journal-title":"Biomedicines"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.75582","article-title":"Carpal tunnel syndrome as a potential indicator of cardiac amyloidosis: a systematic review and meta-analysis","volume":"16","author":"Elghouneimy MA","year":"2024","unstructured":"Elghouneimy MA, Bushara N, Abdelwahab OA, Makableh AA, Alnabwy DM, Diab RA. Carpal tunnel syndrome as a potential indicator of cardiac amyloidosis: a systematic review and meta-analysis. Cureus. 2024, 16:e75582. 10.7759\/cureus.75582","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15035","article-title":"Transthyretin cardiac amyloid: broad heart failure phenotypic spectrum and implications for diagnosis","volume":"11","author":"Alonso M","year":"2024","unstructured":"Alonso M, Neicheril RK, Manla Y, et al.. Transthyretin cardiac amyloid: broad heart failure phenotypic spectrum and implications for diagnosis. ESC Heart Fail. 2024, 11:3649-55. 10.1002\/ehf2.15035","journal-title":"ESC Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.06.006","article-title":"Racial and genetic differences in presentation of transthyretin amyloid cardiomyopathy with impaired left ventricular function","volume":"10","author":"Martyn T","year":"2022","unstructured":"Martyn T, Saef J, Dey AR, et al.. Racial and genetic differences in presentation of transthyretin amyloid cardiomyopathy with impaired left ventricular function. JACC Heart Fail. 2022, 10:689-91. 10.1016\/j.jchf.2022.06.006","journal-title":"JACC Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3445","article-title":"Heart failure in Europe: guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction\u00a0-\u00a0the ESC EORP Heart Failure III Registry","volume":"26","author":"Lund LH","year":"2024","unstructured":"Lund LH, Crespo-Leiro MG, Laroche C, et al.. Heart failure in Europe: guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction\u00a0-\u00a0the ESC EORP Heart Failure III Registry. Eur J Heart Fail. 2024, 26:2487-501. 10.1002\/ejhf.3445","journal-title":"Eur J Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and writing committee of the universal definition of heart failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt B","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, et al.. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and writing committee of the universal definition of heart failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021, 23:352-80. 10.1002\/ejhf.2115","journal-title":"Eur J Heart Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.02.007","article-title":"Management of heart failure with improved ejection fraction: current evidence and controversies","volume":"13","author":"Kodur N","year":"2025","unstructured":"Kodur N, Tang WH. Management of heart failure with improved ejection fraction: current evidence and controversies. JACC Heart Fail. 2025, 13:537-53. 10.1016\/j.jchf.2025.02.007","journal-title":"JACC Heart Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore JD","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al.. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016, 133:2404-12. 10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2020.08.027","article-title":"Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution","volume":"14","author":"Poterucha TJ","year":"2021","unstructured":"Poterucha TJ, Elias P, Bokhari S, et al.. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution. JACC Cardiovasc Imaging. 2021, 14:1221-31. 10.1016\/j.jcmg.2020.08.027","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano A","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, et al.. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016, 1:880-9. 10.1001\/jamacardio.2016.2839","journal-title":"JAMA Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala S","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, et al.. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019, 26:2065-123. 10.1007\/s12350-019-01760-6","journal-title":"J Nucl Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-020-02396-7","article-title":"Prognostic significance of incidental suspected transthyretin amyloidosis on routine bone scintigraphy","volume":"29","author":"Suomalainen O","year":"2022","unstructured":"Suomalainen O, Pilv J, Loimaala A, M\u00e4tzke S, Heli\u00f6 T, Uusitalo V. Prognostic significance of incidental suspected transthyretin amyloidosis on routine bone scintigraphy. J Nucl Cardiol. 2022, 29:1021-9. 10.1007\/s12350-020-02396-7","journal-title":"J Nucl Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2020.09.372","article-title":"Guideline-directed medical therapy may not be harmful in patients with transthyretin cardiac amyloidosis and heart failure with reduced ejection fraction","volume":"26","author":"Rohm CL","year":"2020","unstructured":"Rohm CL, Howard B, Lakhani B, Britt A, Wilkie J, Snipelisky D. Guideline-directed medical therapy may not be harmful in patients with transthyretin cardiac amyloidosis and heart failure with reduced ejection fraction. J Card Fail. 2020, 26:S129. 10.1016\/j.cardfail.2020.09.372","journal-title":"J Card Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou A","year":"2023","unstructured":"Ioannou A, Massa P, Patel RK, et al.. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023, 44:2893-907. 10.1093\/eurheartj\/ehad347","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari A","year":"2024","unstructured":"Porcari A, Cappelli F, Nitsche C, et al.. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2024, 83:2411-22. 10.1016\/j.jacc.2024.03.429","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg FL","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012, 126:1286-300. 10.1161\/CIRCULATIONAHA.111.078915","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13360","article-title":"Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy","volume":"8","author":"Devesa A","year":"2021","unstructured":"Devesa A, Camblor Blasco A, Pello L\u00e1zaro AM, et al.. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. ESC Heart Fail. 2021, 8:2856-65. 10.1002\/ehf2.13360","journal-title":"ESC Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/363842-an-unusual-case-of-transthyretin-cardiac-amyloidosis-presenting-as-heart-failure-with-improved-ejection-fraction-without-left-ventricular-hypertrophy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:17:19Z","timestamp":1746083839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/363842-an-unusual-case-of-transthyretin-cardiac-amyloidosis-presenting-as-heart-failure-with-improved-ejection-fraction-without-left-ventricular-hypertrophy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.83283","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}